Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma

Hepatology Research

Volumn 40, Issue 5, 2010, Pages 550-554

  Kuroda, Hidekatsu ^a   Kasai, Kazuhiro ^a   Kakisaka, Keisuke ^a   Yasumi, Yuki ^a   Kataoka, Koujiro ^a   Ushio, Akira ^a   Miyamoto, Yasuhiro ^a   Sawara, Kei ^a   Oikawa, Kanta ^a   Kondo, Koryo ^a   Miura, Yoshiaki ^a   Endo, Ryujin ^a   Takikawa, Yasuhiro ^a   Suzuki, Kazuyuki ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Child Pugh score; Hepatocellular carcinoma; Liver cirrhosis; Liver function parameters; Percutaneous radiofrequency ablation therapy

Indexed keywords

ALBUMIN; BILIRUBIN;

AGED; ALBUMIN BLOOD LEVEL; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; CANCER RECURRENCE; CANCER RISK; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

EID: 77954373045     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00613.x     Document Type: Article

References (19)

1. Wong F, Choi T. Primary liver cancer. Asian experience. Surgery of Liver and Biliary Tract 1988, 1135-51. Blumgart L, ed., London, Churchill-Livingstone
2. Tsuzuki T, Sugioka A, Ueda M. Hepatic resection for hepatocellular carcinoma. Surg 1990, 107:511-20.
3. Mazzaferro V, Regalia E, Doci R. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 14(334):693-9.
4. Shiina S, Teratani T, Obi S, Hamamura K, Koike Y, Omata M. Nonsurgical treatment of hepatocellular carcinoma: from percutaneous ethanol injection therapy and percutaneous microwave coagulation therapy to radiofrequency ablation. Oncology 2002, 62(1):64-8. Suppl
5. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002, 235:466-86.
6. Balsells J, Charco R, Lazaro JL. Resection of hepatocellular carcinoma in patients with cirrhosis. Br J Surg 1996, 83:758-61.
7. Kudo M. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology 2008, 75(1):30-41. Suppl
8. Koike Y, Yoshida H, Shiina S. Changes in hepatic functional reserve after percutaneous tumor ablation for hepatocellular carcinoma: long-term follow up for 227 consecutive patients with a single lesion. Hepatol Int 2007, 1:295-301.
9. Ebara M, Kita K, Sugiura N. Therapeutic effect of percutaneous ethanol injection on small hepatocellular carcinoma: evaluation with CT. Radiology 1995, 195:371-7.
10. Pugh RWH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding esophageal varices. Br J Surg 1983, 60:646-9.
11. Hoshida Y, Shiratori Y, Koike Y. Hepatic volumetry to predict adverse events in percutaneous ablation of hepatocellular carcinoma. Hepatogastroenterol 2002, 49:451-5.
12. Kayaalp C, Arda K, Oto A, Oran M. Liver volume measurement by spiral CT: an in vitro study. Clin Imaging 2002, 26:122-4.
13. Koda M, Ueki M, Maeda Y. The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res 2004, 29:18-23.
14. Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol 2009, 43:580-5.
15. Muto Y, Sato S, Watanabe A. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-13.
16. Muto Y, Sato S, Watanabe A. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006, 35:204-14.
17. Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004, 1(19):779-88.
18. Okabayashi T, Nishimori I, Sugimoto T. Effects of branched-chain amino acids-enriched nutrient support for patients undergoing liver resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2008, 23:1869-73.
19. Takeshita S, Ichikawa T, Nakao K. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemoembolization for hepatocellular carcinoma. Nutr Res 2009, 29:89-93.